Integrated deep learned transcriptomic and structure-based predictor of clinical trials outcomes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Despite many recent advances in systems biology and a marked increase in the availability of high-throughput biological data, the productivity of research and development in the pharmaceutical industry is on the decline. This is primarily due to clinical trial failure rates reaching up to 95% in oncology and other disease areas. We have developed a comprehensive analytical and computational pipeline utilizing deep learning techniques and novel systems biology analytical tools to predict the outcomes of phase I/II clinical trials. The pipeline predicts the side effects of a drug using deep neural networks and estimates drug-induced pathway activation. It then uses the predicted side effect probabilities and pathway activation scores as an input to train a classifier which predicts clinical trial outcomes. This classifier was trained on 577 transcriptomic datasets and has achieved a cross-validated accuracy of 0.83. When compared to a direct gene-based classifier, our multi-stage approach dramatically improves the accuracy of the predictions. The classifier was applied to a set of compounds currently present in the pipelines of several major pharmaceutical companies to highlight potential risks in their portfolios and estimate the fraction of clinical trials that were likely to fail in phase I and II.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403 · cited 2×
“This procedure contributed to improving the drug discovery process by providing a set of practical filters for many drug development pipelines (Leeson and Springthorpe 2007).”
BackgroundMethodDiagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“Throughout the last decade many studies have revealed a continuous increase in the total cost of developing successful pharmaceutical products (Munos and Chin 2011; Mignani et al. 2016; Scannell et al. 2012).”
BackgroundPID: the Pathway Interaction Database
Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., & Buetow, K. H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn653 · Cited by 1,603
Makhzani, A., Shlens, J., Jaitly, N., Goodfellow, I., & Frey, B. (2015) · arXiv · doi:10.48550/arxiv.1511.05644 · Cited by 1,579
The SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451
Applications of Deep Learning in Biomedicine
Mamoshina, P., Vieira, A., Lane, E., & Zhavoronkov, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00982 · Cited by 701
Self-citation
Cited by
Opportunities and obstacles for deep learning in biology and medicine
Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., Ferrero, E., Agapow, P.-M., Zietz, M., Hoffman, M. M., et al. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0387 · Cited by 2,310
Kadurin, A., Nikolenko, S., Khrabrov, K., Aliper, A., & Zhavoronkov, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00346 · Cited by 587
“[7, 8], drug discovery [4, 9, 10], predicting clinical trial outcomes [11], and generating”
BackgroundSelf-citationArtificial intelligence in drug development
Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G., Li, X., Wu, J. C., & Yang, S. (2025) · Nature Medicine · doi:10.1038/s41591-024-03434-4 · Cited by 498
Xu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03743-2 · Cited by 180
Self-citationWill Artificial Intelligence for Drug Discovery Impact Clinical Pharmacology?
Zhavoronkov, A., Vanhaelen, Q., & Oprea, T. I. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1795 · Cited by 159
Self-citationArtificial intelligence (ai) systems for interpreting complex medical datasets
Altman, R. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.650 · Cited by 65
Metadata
- Authors
- Artemov, A. V., Putin, E., Vanhaelen, Q., Aliper, A., Ozerov, I. V., & Zhavoronkov, A.
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2016-12-20
- OpenAlex
- W2571816515
- Cited by
- 40
- References
- 14
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.